Framycetin

Summary

Framycetin (CHEMBL184618) is an approved small-molecule antibacterial drug (ATC R01AX08) targeting CASR; indicated across 3 conditions including eye infectious disorder and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R01AX08 (+2 more)
• Targets: 1 (CASR)
• Indications: 3 conditions
• Clinical trials: 25
• Chemistry: 614.6 Da · C23H46N6O13

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL184618
Name	Framycetin
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	8378
ChEBI	CHEBI:7508
ATC	R01AX08, D09AA01, S01AA07
Molecular formula	C23H46N6O13
Molecular weight	614.6
InChIKey	PGBHMTALBVVCIT-VCIWKGPPSA-N

SMILES: C1[C@H]([C@@H]([C@H]([C@@H]([C@H]1N)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CN)O)O)N)O[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O[C@@H]4[C@@H]([C@H]([C@@H]([C@@H](O4)CN)O)O)N)O)O)N

IUPAC name: (2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol

ChEBI definition: A tetracyclic antibacterial agent derived from neomycin, being a glycoside ester of neamine and neobiosamine B.

Pharmacological roles (ChEBI): antibacterial drug, allergen.

Other ChEBI roles (chemical / environmental): Escherichia coli metabolite.

Also known as: Actilin, Antibiotic 10676, ANTIBIOTIQUE EF 185, Dekamycin iii, Enterfram, Fradiomycin b, Framicetina, Framidal, Framycetin, Framycetine, Framycin, Framygen

Parent form; salt/anhydrous children: CHEMBL1950493, CHEMBL3188205

Patent coverage: 64,785 distinct patent families (217,461 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CASR	CaS receptor	Full agonist	4	0.1%	P41180

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Menin, Lecithin retinol acyltransferase, Bacterial 70S ribosome, Lethal factor, Transient receptor potential cation channel subfamily V member 1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15917	8.15	Ki	7	nM	CHEMBL_ACT_24867630
P02358	7.5	IC50	32	nM	CHEMBL_ACT_5099164
TRPV1	6.4	IC50	400	nM	CHEMBL_ACT_14552319
P15917	6.3	Ki	500	nM	CHEMBL_ACT_1771112

Target pathways

Aggregated over 1 target gene(s): CASR.

Top Reactome pathways

7 total, by targets touching each:

Pathway	Targets	Genes
Signal Transduction	1	CASR
Signaling by GPCR	1	CASR
GPCR downstream signalling	1	CASR
G alpha (q) signalling events	1	CASR
G alpha (i) signalling events	1	CASR
Class C/3 (Metabotropic glutamate/pheromone receptors)	1	CASR
GPCR ligand binding	1	CASR

Dominant GO biological processes

GO term	Targets
ossification	1
response to ischemia	1
detection of calcium ion	1
intracellular calcium ion homeostasis	1
G protein-coupled receptor signaling pathway	1
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
JNK cascade	1
chemosensory behavior	1
positive regulation of cell population proliferation	1
anatomical structure morphogenesis	1
positive regulation of gene expression	1
positive regulation of insulin secretion	1
bile acid secretion	1
cellular response to hepatocyte growth factor stimulus	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye infectious disorder	3	MONDO:0043885	EFO:1001888
osteomyelitis	0	MONDO:0005246	EFO:0003102

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 25.

Phase distribution

Phase	Trials
Not specified	11
PHASE2	5
PHASE4	4
EARLY_PHASE1	2
PHASE1	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03663504	PHASE4	ACTIVE_NOT_RECRUITING	Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery
NCT06148025	PHASE4	RECRUITING	Antibiotics and Vaccine Immune Responses Study
NCT02652637	PHASE4	UNKNOWN	MOBILE Trial. Mechanical and Oral Antibiotic Bowel Preparation Versus no Bowel preparatIon for eLEctive Colectomy - a Multicenter, Prospective, Randomized, Controlled Trial.
NCT05593601	PHASE4	UNKNOWN	Decolonization of Carbapenem-resistant Enterobacterales (CRE) in Patients With Faecal Carriage of CRE With Neomycin
NCT00534391	PHASE3	UNKNOWN	Comparison of Combination Antibiotics Eyedrop to Artificial Tear in Hordeolum After Incision and Curettage
NCT04729322	PHASE2	ACTIVE_NOT_RECRUITING	Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
NCT02472600	PHASE2	UNKNOWN	Eradication of Antibiotic-resistant Bacteria Through Antibiotics and Fecal Bacteriotherapy
NCT02730962	PHASE2	TERMINATED	Interventional Bioremediation of Microbiota in Metabolic Syndrome
NCT02765256	PHASE2	COMPLETED	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease
NCT03476317	PHASE2	COMPLETED	Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn’s Disease
NCT07490054	PHASE1	RECRUITING	Intestinal Microbiota Transplantation in Patients With Chronic Heart Failure
NCT02001909	PHASE1	COMPLETED	Effect of Neomycin on the Pharmacokinetics of Regorafenib
NCT01638429	EARLY_PHASE1	COMPLETED	Role of Methane in Glycemic Control
NCT03042091	EARLY_PHASE1	UNKNOWN	Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
NCT00166868	Not specified	COMPLETED	Use of Probiotics to Prevent Cholangitis in Children With Biliary Atresia After the Kasai Portoenterostomy
NCT00355602	Not specified	COMPLETED	Antibiotics for the Treatment of Ulcerative Colitis
NCT00945334	Not specified	COMPLETED	Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
NCT00997139	Not specified	COMPLETED	Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment
NCT01097811	Not specified	UNKNOWN	Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy
NCT02154061	Not specified	COMPLETED	Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics
NCT02604849	Not specified	COMPLETED	Efficacy of Intestinal Decontamination in Patients Colonized by Carbapenem-resistant Klebsiella Pneumoniae and Colistin
NCT03593252	Not specified	UNKNOWN	Bowel Preparation in Elective Pediatric Colorectal Surgery
NCT03856671	Not specified	COMPLETED	Prophylatic Effect Preoperative Antibiotics With Mechanical Bowel Preparation in SSIs
NCT05999955	Not specified	COMPLETED	Safety and Efficacy of DSM 32444 Postbiotic in the Treatment of Acute Rhinosinusitis
NCT07286851	Not specified	COMPLETED	Do Topical Antibiotics Improve Skin Graft Results?

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (1) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for amikacin, dibekacin, gentamicin, kana	CPIC	MT-RNR1		yes

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

8 molecules share ≥1 primary target. Top 8 by shared-target count:

Molecule	Source	Status	Shared targets
CINACALCET	ChEMBL + PubChem	Phase 4 (approved)	CASR
ENCALERET	ChEMBL	Phase 3	CASR
EVOCALCET	ChEMBL	Phase 3	CASR
FENDILINE	ChEMBL	Phase 2	CASR
RONACALERET	ChEMBL	Phase 2	CASR
SB-423562	ChEMBL	Phase 2	CASR
TECALCET	ChEMBL	Phase 2	CASR
tryptophan	PubChem	Approved	CASR